Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)

ClinicalTrials.gov ID: NCT02474407

Public ClinicalTrials.gov record NCT02474407. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Randomized, Crossover Pharmacokinetic Study to Determine the Bioavailability, Safety and Tolerability of Single Doses of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®) in Patients With Refractory Epilepsy

Study identification

NCT ID
NCT02474407
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Acorda Therapeutics
Industry
Enrollment
78 participants

Conditions and interventions

Interventions

  • diazepam nasal spray Drug
  • diazepam rectal gel Drug

Drug

Eligibility (public fields only)

Age range
12 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2015
Primary completion
Apr 30, 2016
Completion
Jun 30, 2016
Last update posted
Oct 15, 2018

2015 – 2016

United States locations

U.S. sites
22
U.S. states
16
U.S. cities
21
Facility City State ZIP Site status
Acorda Site #115 Little Rock Arkansas 72205
Acorda Site #127 Washington D.C. District of Columbia 20010
Acorda Site #101 Tampa Florida 33606
Acorda Site #125 Honolulu Hawaii 96817
Acorda Site #104 Lexington Kentucky 40513
Acorda Site #111 Baltimore Maryland 21201
Acorda Site #102 Bethesda Maryland 20817
Acorda Site #110 Ann Arbor Michigan 48105
Acorda Site #117 Jackson Mississippi 39216
Acorda Site #112 St Louis Missouri 63131
Acorda Site #128 Edison New Jersey 08818
Acorda Site #121 Hackensack New Jersey 07601
Acorda Site #123 Amherst New York 14226
Acorda Site #119 Rochester New York 14642
Acorda Site #132 Chapel Hill North Carolina 27599
Acorda Site #114 Portland Oregon 97239
Acorda Site #116 Philadelphia Pennsylvania 19104
Acorda Site #105 Philadelphia Pennsylvania 19107
Acorda Site #130 Memphis Tennessee 38105
Acorda Site #103 Bellaire Texas 77401
Acorda Site #122 Dallas Texas 75251
Acorda Site #108 Houston Texas 77004

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02474407, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 15, 2018 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02474407 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →